Business Context and Reporting Period
This Form 8-K Current Report was filed by Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) on October 2, 2024. The filing documents a corporate name change effective as of 4:00 p.m. Eastern Time on October 2, 2024. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Global Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Corporate Name: Changed from "Eliem Therapeutics, Inc." to "Climb Bio, Inc."
- Trading Symbol: The new trading symbol on The Nasdaq Global Market is "CLYM".
- Effective Date: The name change and new trading symbol became effective on October 2, 2024, with trading under the new symbol expected to commence on October 3, 2024.
- Corporate Documents: The Company amended its Amended and Restated Certificate of Incorporation and restated its Bylaws solely to reflect the name change.
- Stockholder Rights: The filing states that the name change does not affect the rights of the Company's stockholders.
- CUSIP Number: The CUSIP number for the common stock remains unchanged.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document is limited to the procedural details of the name change.
Investor Verification Checklist
- Verify the new trading symbol "CLYM" on The Nasdaq Global Market starting October 3, 2024.
- Confirm that the CUSIP number for existing holdings remains unchanged.
- Review the attached Certificate of Amendment (Exhibit 3.1) and Amended and Restated Bylaws (Exhibit 3.2) for any non-name-related provisions.
- Monitor future filings for the first financial report issued under the new corporate name.